EFV - iShares MSCI EAFE Value ETF

BATS - BATS Delayed Price. Currency in USD
49.50
+0.34 (+0.69%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close49.16
Open49.42
Bid0.00 x 800
Ask0.00 x 800
Day's Range49.39 - 49.73
52 Week Range48.93 - 59.57
Volume456,705
Avg. Volume584,248
Net Assets5.86B
NAV51.98
PE Ratio (TTM)N/A
Yield4.25%
YTD Return-3.35%
Beta (3Y Monthly)1.03
Expense Ratio (net)0.38%
Inception Date2005-08-01
  • Morningstar24 days ago

    A Well-Diversified Foreign-Stock Fund With a Value Tilt

     Schwab Fundamental International Large Company Index ETF FNDF is a compelling alternative. FNDF is a solid low-cost fund that weights its holdings by fundamental measures of size, giving it a value orientation. This contrarian approach introduces a value tilt to the portfolio, and its price/book ratio is in line with the MSCI World ex USA Value Index.

  • ETF Trends3 months ago

    3 ETFs to Watch When Value Investing Makes a Comeback

    CNBC recently highlighted the woes of Greenlight Capital hedge fund manager David Einhorn, a noted value investor, who has investors fleeing his fund after posting an 18.7 percent loss year-to-date and a 7.7 percent loss in the month of June alone. The latest bull market since February has been largely attributed to returns seen in stocks featuring high-growth and momentum, according to Robert Buckland of Citi Research. "This usually favors growth and momentum trades and has produced bubbles in the past," said Buckland.

  • Ideas To Enhance Potential Returns In Global Bull Market Rally
    Investor's Business Daily9 months ago

    Ideas To Enhance Potential Returns In Global Bull Market Rally

    CLS Investments' Rusty Vanneman offers ETF picks for investors with a globally balanced portfolio to enhance potential returns.

  • What’s Teva Pharmaceutical’s Research and Development Strategy?
    Market Realist9 months ago

    What’s Teva Pharmaceutical’s Research and Development Strategy?

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? In December 2017, Teva Pharmaceutical Industries (TEVA) laid out a detailed restructuring plan for the company to turn around its ailing business due to a number of challenges it’s facing.